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POTENSI TERAPEUTIK SEL STEM NEURAL MANUSIA ARUHAN 
SECARA HIPOKSI DAN FRAKSI KAYA DENGAN BAICALEIN UNTUK 
MODEL STROK ISKEMIA IN VITRO 
ABSTRAK 
 
Strok iskemia merupakan punca utama kematian di Malaysia selepas penyakit 
jantung dan barah. Kaedah rawatan biasa tidak mampu memulih dan menjana semula 
tisu otak pesakit yang mati. Sel stem neural dewasa dalam otak juga tidak mampu 
memulih tisu tersebut berikutan kadar penjanaan sel neuron yang terhad gagal 
membentuk jaringan saraf. Oleh yang demikian, pesakit strok berisiko tinggi untuk 
serangan semula. Kaedah alternatif berasaskan terapeutik adalah penting untuk 
meningkatkan pemulihan strok. Mutakhir ini, transplantasi sel stem neural manusia 
telah menjadi pendekatan terbaik untuk rawatan penyakit neurodegeneratif termasuk 
strok. Namun demikian, potensi transplantasi sel stem neural adalah terhad kerana 
kegagalan sel tersebut untuk bertahan dalam kawasan iskemia. Kajian ini bertujuan 
untuk mengatasi kelemahan tersebut dengan meningkatkan potensi terapeutik sel 
stem neural melalui aruhan secara hipoksi dan fraksi kaya dengan baicalein (F5). 
Hipoksia paras fisiologi (2% O2) selama 24 jam meningkatkan proliferasi, ketahanan 
dan keupayaan membeza kepada pelbagai jenis sel neural matang. Gen rujukan 
protein ribosom sub unit besar P1 (RPLP1) dan protein ribosom sub unit besar L13A 
(RPL13A) adalah sesuai untuk normalisasi data tindak balas berantai polimerase 
kuantitatif (qPCR) sel stem neural aruhan secara normoksi dan hipoksi. Aruhan 
hipoksia mengaktifkan isyarat perlindugan dalam sel melalui transkripsi faktor 
pendorongan hipoksia-1 alfa (HIF-1α), faktor pertumbuhan endotelial vaskular A 
(VEGFA), angiopoietin 1 (ANGPT1), protein homolog 1 notch lokus neurogenik  
xxxiv 
 
(Notch 1), faktor berkait 2-eritroid faktor nukleus 2 (Nrf2) and dismutasi natrium 
(SOD1). F5 dipilih sebagai agen aruhan kerana mengandungi baicalein yang 
merupakan penstabil HIF-1α mimik aruhan hipoksi walaupun dalam keadaan 
normoksia. Sel stem neural diaruh dengan 1.56 µg/mL F5 selama 24 jam juga 
meningkatkan proliferasi, ketahanan dan potensi sel stem neural untuk menjana sel 
otak matang. Hipoksanthin fosforibosil transferas (HPRT1) dan RPL13A adalah gen 
rujukan paling stabil bagi sel stem neural kawalan (0.1% DMSO) dan aruhan secara 
F5. Seperti hipoksia, aruhan F5 mendorong kepada pengaktifan HIF-1α, VEGFA, 
ANGPT1, Notch 1, Nrf2 and SOD1. Sel stem neural aruhan secara hipoksi dan F5 
digunakan untuk merawat model strok iskemia in vitro (IVIS). Aruhan F5 
menunjukkan kelebihan pertumbuhan lebih pantas menghampiri model IVIS 
berbanding aruhan hipoksia. Faktor pelindung berpontesi yang dirangsang oleh 
aruhan hipoksia mempunyai jangka hayat singkat dalam keadaan beroksigen. Aruhan 
F5 merangsang faktor perlindungan berpotensi yang stabil tanpa dipengaruhi oleh 
oksigen. Aruhan secara hipoksi dan F5 telah meningkatkan potensi terapeutik sel 
stem neural untuk terapeutik strok. Kajian ini menunjukkan bahawa sel stem neural 
diaruh F5 terbukti mempunyai potensi terapeutik yang tinggi, di samping sesuai 
digunakan secara klinikal untuk rawatan strok iskemia pada masa hadapan.  
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THERAPEUTIC POTENTIALS OF HYPOXIC- AND BAICALEIN-
ENRICHED FRACTION-PRECONDITIONED HUMAN NEURAL STEM 
CELLS FOR IN VITRO ISCHEMIC STROKE MODEL 
ABSTRACT 
 
Ischemic stroke is the third leading cause of death in Malaysia, closely after 
heart disease and cancer. Standard treatments for stroke are not totally efficient to 
repair and regenerate the damaged brain tissue and there are possibilities for the 
recurrence. Replacement by endogenous adult neural stem cells (NSCs) during 
ischemic stroke was insufficient to repair injury site due to low neuronal turnover 
that could integrate into functional neuron network. Therefore, it is imperative to 
develop alternative therapeutic strategies to improve stroke recovery. Recently, 
human NSC grafting has emerged as encouraging approach for treating stroke. 
Nonetheless, the therapeutic potential of NSC-based treatment is limited, mainly due 
to a large number of implanted cells died after grafting into the injury site. To 
circumvent this problem, this study aimed to enhance therapeutic potentials of 
human NSCs prior to transplantation through hypoxic and baicalein-enriched fraction 
(F5) preconditioning. Hypoxic preconditioning under 2% O2 for 24 h enhanced NSC 
self-renewal, survival and multipotency. 60S ribosomal protein large P1 (RPLP1) 
and ribosomal protein L13A (RPL13A) were the most reliable reference genes for 
qPCR normalization of normoxic- and  hypoxic-preconditioned NSCs. Hypoxic 
preconditioning induced innate neuroprotective signaling through transcriptional 
activation of hypoxia-inducible factor-1 alpha (HIF-1α), vascular endothelial growth 
factor A (VEGFA), angiopoietin 1 (ANGPT1), neurogenic locus notch homolog 
protein 1 (Notch 1), nuclear factor erythroid 2-related factor 2 (Nrf2) and sodium  
xxxvi 
 
dismutase 1 (SOD1). Based on the HIF-1α stabilization potential of baicalein at 
ambient conditions, F5 was postulated to trigger effects mimic hypoxic 
preconditioning under normoxia. Interestingly, preconditioning with 1.56 µg/mL of 
F5 for 24 h increased NSC proliferation, viability and lineage specific differentiation. 
Hypoxanthine phosphoribosyl transferase 1 (HPRT1) and RPL13A were the most 
stably expressed reference genes for qPCR normalization of control (0.1% DMSO) 
and F5-preconditioned NSCs. Moreover, F5 preconditioning stimulated hypoxia-
mimetic signaling intrinsically via HIF-1α, VEGFA, ANGPT1, Notch 1, Nrf2 and 
SOD1 upregulation. Both hypoxic- and F5-preconditioned NSCs were applied to in 
vitro ischemic stroke (IVIS) model on wound-healing based culture slide for 72 h of 
live imaging. F5-preconditioned NSCs accelerated migration and homing towards 
IVIS model over an experimental period of 72 h compared to hypoxic-
preconditioned NSCs. The neuroprotective factors induced by hypoxic 
preconditioning are postulated to degrade rapidly when exposed to oxygen. 
Contrarily, F5-preconditioned NSCs attained intrinsic neuroprotective mechanisms 
without compromising their stability under normoxia. In conclusion, both the 
hypoxic and F5 preconditioning had successfully enhanced therapeutic potentials of 
NSCs for ischemic stroke. F5-preconditioned NSCs with enhanced therapeutic 
efficacy was more likely to be applicable in clinical setting and thus could be a 







Stroke, the nation’s third leading cause of death, leading to severe and long-term 
functional disability (Loo and Gan, 2012; Cheah et al., 2016). In Malaysia, most 
patients had ischemic stroke rather than hemorrhagic stroke (Jaya et al., 2002). 
Ischemic stroke is characterized by thrombotic or embolic occlusion of cerebral 
artery, thereby restricts oxygen, nutrients and glucose supplies to an area of the brain 
(Figure 1.1A). In contrary, hemorrhagic stroke is characterized by rupture of a blood 
vessel on or within the brain, subsequently causing severe bleeding into brain 
parenchyma (Figure 1.1B). According to National Health and Morbidity Survey 
(NHMS), the prevalence of stroke among Malaysians increased between 2006 and 
2011 (Cheah et al., 2016). As a result, stroke causes an economic burden on      









    
 
                       
Figure 1.1 A diagram illustrating (A) ischemic stroke and (B) hemorrhagic 
stroke. Ischemic stroke occurs when a clot blocks blood flow to an 
area of the brain. Hemorrhagic stroke occurs when blood vessels 
rupture causing blood leakage into cerebral parenchyma. Figure is 














1.1.1 Pathophysiologic cascades in ischemic stroke 
Ischemic stroke initiates a cascade of pathophysiologic cellular and molecular 
mechanisms such as energy failure, ionic imbalance, glutamate excitotoxicity, 
inflammation and free radical overload, resulting in irreversible brain damage     
(Deb et al., 2010). 
 
1.1.1(a) Energy failure 
Glucose is the primary energy source for the brain (Mergenthaler et al., 2013). 
Nonetheless, the brain does not store glucose and hence requires a constant supply of 
glucose (Berg et al., 2002). Due to high energy consumption, abundance 
mitochondria are present in neurons (Misgeld and Schwarz, 2017). Under 
physiological conditions, neurons depend mainly on mitochondrial oxidative 
phosphorylation (OXPHOS) as the main source of adenosine triphosphate (ATP) 
(Figure 1.2A) (Zheng et al., 2016). This is because OXPHOS generates energy in the 
form of 36 molecules of ATP for each molecule of glucose (Valvona et al., 2015).  
 
Glucose is metabolized to pyruvate through glycolysis (Valvona et al., 2015). This 
process also generates ATP and nicotinamide adenine dinucleotides (NADH). 
Pyruvate enters mitochondria and gets oxidized into acetyl-coA, CO2 and NADH. 
Acetyl-coA is subsequently oxidized in tricarboxylic acid cycle (TCA). TCA cycle 
provide NADH and flavin adenine dinucleotides (FADH2) which carry the high-
energy electron for OXPHOS at the inner mitochondrial membrane                 
(Lodish et al., 2000). The inner mitochondrial membrane comprises complex I, II, 
III, IV and V. During OXPHOS, electron transport chain (ETC) passes electrons 
released from reduced form of NADH and FADH2 to complex I and II, respectively      
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Figure 1.2 An overview of energy metabolism in the brain under (A) physiological conditions and (B) after ischemic stroke. (A) Glucose is 
converted into pyruvate via glycolysis in the cytosol. Pyruvate is transported into the mitochondria and oxidized to form        
acetyl-coA. Acetyl-coA is subsequently oxidized via TCA cycle, releasing NADH, FADH2 and ATP. The electrons transfer from 
reduced NADH and FADH2 to oxygen in a series of redox reactions. These reactions released free energy in a form of H
+
 gradient 
across the inner mitochondrial membrane, resulting in ATP synthesis via chemiosmosis. (B) Due to disrupted blood flow, oxygen 
and glucose levels eventually drop too low for mitochondrial OXPHOS, causing oxidative stress on mitochondria. To compensate 
the energy supply, glucose is converted into pyruvate via anaerobic glycolysis to meet the metabolic demands. Pyruvate is then 
converted into the lactate and H
+
. Nevertheless, these reactions generate only 2 molecules of ATP for each molecule of glucose. 
Ultimately, anaerobic glycolysis fails to compensate the high energy demand of brain cells, leading to energy exhaustion. High 
accumulation of lactate and H
+




(Lodish et al., 2000). Electrons are then transferred from both complexes to 
coenzyme Q (coQ). Coenzyme Q transports electrons to complex III and then to 
cytochrome c (Cyt c). The ETC ends at complex IV where electrons reduce oxygen 
in the presence of proton (H
+
) to water. The electrons transfer across complex I, III 
and IV is also coupled to H
+
 transfer, hence, generating a H
+
 gradient across the 
inner mitochondrial membrane (Lodish et al., 2000).  Complex V uses the free 
energy released from H
+
 gradient along with ATP synthase to convert adenosine 
diphosphate (ADP) and inorganic phosphate (Pi) into ATP.  
 
In brain, neurons constantly demand for high glucose to perform basic cellular 
processes such as protein synthesis and energy production (Bélanger et al., 2011; 
Niven, 2016). Complete loss of blood flow to the brain for only 5 min is deadly to 
neurons (Lipton, 1999). During ischemic stroke, interruption of blood flow attributes 
to oxygen and glucose deprivation (OGD). Upon OGD insults, continuous 
consumption of oxygen and glucose diminish their availability for mitochondrial 
OXPHOS and ATP generation (Figure 1.2B). Following that, the glucose 
metabolism switches from aerobic to anaerobic glycolysis for ATP production until 
glucose is completely depleted (Solaini et al., 2010). Nevertheless, the efficiency of 
ATP production by anaerobic glycolysis is much lower compared to mitochondrial 
OXPHOS in which only 2 molecules of ATP produced for each molecule of glucose 
under anaerobic conditions. Unfortunately, consumption exceeds production and 
drives energy failure in the brain. In addition, anaerobic glycolysis also produces H
+
 
and lactate, lowering the pH and causing rapid intracellular acidosis                
(Solaini et al., 2010).  
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1.1.1(b)      Ionic imbalance 
Under physiological conditions, the potassium ion (K
+
) level has higher 
concentrations intracellular than extracellular (Figure 1.3A) (Cheng et al., 2013). 
However, the intracellular levels of sodium ion (Na
+
) and calcium ion (Ca
2+
) are 
lower than extracellular (Cheng et al., 2013). Following rapid ATP deficit, activity of 











-ATPase pumps are reduced (Figure 1.3B). As consequence, the K
+ 
channels 
open and permit K
+ 
to move outward, leading to accumulation of extracellular K
+
 





across the plasma membrane (Reading and Isbir, 1980). The Na
+ 
channels close and retain Na
+ 
intracellular, leading to accumulation of Na
+ 
in the 
cells and depolarization of the membrane potential. Hyperpolarized cells also 




 is an 
intracellular messenger participating in many cellular processes, particularly in signal 
transduction pathways (Hofer and Lefkimmiatis, 2007). Overload of Ca
2+
 in the cell 
further contributes to collapse of membrane potential. Ionic imbalances also induce 
transient osmotic gradients in the brain as water influx towards area of high Na
+
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 levels are lower intracellular. (B) Due to 
disrupted blood flow, oxygen and glucose levels eventually drops too low for energy metabolism, causing rapid declination of 










-ATPase pumps fail 
to distribute respective ions across the membrane, leading to ionic imbalance. The effects of changes in ion concentration gradient 





1.1.1(c) Glutamate excitotoxicity 
Neurotransmitters are chemical messengers that enable excitatory or inhibitory 
neurotransmission to pass an electrical or chemical signal from a neuron to a target 
neuron across the synapse (Deutch, 2013). Glutamate is an amino acid-based 
excitatory neurotransmitter which constitutes for over 90% of the synapses in human 
brain (Hofmeijer and van Putten, 2012). It is a non-essential amino acid derived from 
reductive amination of a TCA cycle intermediate, α-ketoglutarate                
(Schousboe et al., 2014). Alternatively, glutamate can be synthesized from 
hydrolysis of glutamine by phosphate activated glutaminase in presynaptic neuron or 
surrounding glial cells (Schousboe et al., 2014). Under physiological conditions, 
glutamate is cleared from the synaptic cleft by Na
+
-coupled glutamate transporters on 
the plasma membrane of presynaptic terminal and glial cells. In the presynaptic 
terminal, glutamate is stored in vesicles at the axon (Figure 1.4A). In glial cells, 
glutamate is converted to glutamine by glutamine synthase in the presence of ATP 
before being transported back to presynaptic terminal. The glutamine is then recycled 
for glutamate synthesis in the presynaptic terminal. However, under OGD conditions, 









, which facilitate release of glutamate from the synaptic vesicles 
into the synaptic cleft (Grewer et al., 2008). Excess accumulation of extracellular 
glutamate over-activates the glutamate receptors. Following excitatory stimulation, 
massive extracellular Ca
2+
 enters the postsynaptic neuron through ionotropic 
glutamate receptors such as N-methyl-D-aspartate receptors (NMDARs), leading to 
phospholipases and proteases accumulation which perturbed the cellular integrity 
(Figure 1.4B). Ultimately, glutamate excitotoxicity triggers depolarization of 
postsynaptic neuron, leading to neuronal death (Grewer et al., 2008). 
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Figure 1.4 Glutamate homeostasis of presynaptic and postsynaptic neurons under (A) physiological conditions and (B) ischemic stroke onset. 
(A) Under basal condition, glutamate transporters remove glutamate (Glu) from extracellular space and stored in vesicles. In glial 
cells, glutamate is converted to glutamine (Gln) by glutamine synthase in the presence of ATP before being transported back to 
presynaptic terminal. The glutamine is then recycled for glutamate synthesis in the presynaptic terminal. The K
+
 level is 




 levels are maintained at lower levels intracellular. (B) Under pathological 








 whilst reducing 
intracellular K
+
, which induce trafficking of glutamate transporters backwards causing glutamate excitotoxicity. Ultimately, 





The onset of ischemic stroke also initiates various inflammatory cascades by 
inflammatory cells such as leucocytes, endothelial cells, astrocytes and microglia to 
produce pro-inflammatory cytokines and adhesion molecules                    
(Lambertsen et al., 2012). Circulating leucocytes then migrate and accumulate in the 
infarcted lesion before secreting pro-inflammatory mediators which trigger 
additional injury on neighboring viable cells surrounding the lesion                  
(Vexler et al., 2006). Microglial cells are resident immune cells in the brain         
(Lull and Block, 2010). Activation of microglia leads to morphologic transformation 
into phagocytes, subsequently exerting macrophagic functions including 
phagocytosis, secretion of pro-inflammatory cytokines and generation of reactive 
oxygen species (ROS) (Lull and Block, 2010). Under pathological conditions,      
pro-inflammatory cytokines promote the infiltration of inflammatory cells from the 
circulation into the tissues (Dinarello, 2009). In addition, accumulation of             
pro-inflammatory cytokines also promotes inflammatory injury through glutamate-
mediated excitotoxicity (Olmos and Lladó, 2014).  
 
1.1.1(e) Free radical production 
Normally, mitochondrial OXPHOS converts oxygen molecules into ATP and water. 
Occasionally, mitochondrial ETC may leak electrons directly to oxygen, resulting in 
free radical formation. Besides mitochondrial ETC, several cytosolic enzymes such 
as xanthine oxidase (XO) also contribute to free radical production                 
(Görlach et al., 2015). Free radicals are oxygen-derived oxidants known as ROS. 





), singlet oxygen (
1
O2) and hydrogen peroxide (H2O2) 
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(Halliwell and Gutteridge, 2015). As illustrated in Figure 1.5A, O2
•- 
is released from 
complex I and II into the matrix during electron transport. In addition, complex III 
also generates O2
•- 
within intermembrane space. The latter could be transported 
through outer mitochondrial membrane by voltage-dependent anion-selective 
channel (VDAC).  
 
Under physiological conditions, ROS is maintained at low levels by intrinsic 
antioxidant systems such as catalases, superoxide dismutase (SOD) and glutathione 
peroxidase (GPx) (Figure 1.5A). In cytosol and intermembrane space of 
mitochondria, SOD1 converts O2
•- 
into H2O2 and water. In mitochondrial matrix, 
SOD2 is responsible for the O2
•- 
dismutation. The glutathione peroxidase enzyme 
(GPx) in the matrix and catalase enzyme in the cytosol catalyse reduction of H2O2 
into water and oxygen.  
 
Upon ischemia, impaired oxygen supply leads to ATP depletion. Due to ongoing 
cellular metabolism and ineffective rephosphorylation, ATP is degraded to 
hypoxanthine. Ca
2+
 influx also activates Ca
2+–dependent protease to oxidize xanthine 
dehydrogenase (XDH) to XO, O2
•-
 and H2O2. However, XO is unable to convert 
hypoxanthine to xanthine in the absence of oxygen, leading to accumulation of 
hypoxanthine. H2O2 is partially reduced to highly damaging 
•
OH. In addition, 





 reacts with H2O2 at higher affinity, giving rise to 
•
OH through stepwise 
reduction of Fenton reaction. Overwhelmed ROS can cause opening of the 
mitochondrial permeability transition pore (MPTP) which irreversibly damage the 





Figure 1.5 Schematic illustration of free radical production and scavenging under 
(A) physiological conditions and (B) after ischemic stroke as indicated 
in red. (A) Under normal conditions, complex I, II and III release O2
•-
 
as byproduct of ETC. Intrinsic antioxidant systems such as SOD1 and 
SOD2 convert O2
•-
 into H2O2 and water. Then, catalase and GPx 
convert H2O2 into oxygen and water. Thus, ROS is maintained at low 
levels. (B) Under ischemia, impaired oxygen and glucose supplies 
cause ATP depletion. Consequently, ATP is degraded to hypoxanthine. 
Ca
2+
 influx activates Ca
2+
-dependent proteases which convert XDH to 
XO, O2
•-
 and H2O2. Due to oxygen deprivation, XO is unable to 
convert hypoxanthine to xanthine. H2O2 is partially reduced to highly 
reactive 
•
OH. Degraded heme proteins release Fe
2+
 which react with 
H2O2 to form highly reactive 
•
OH. ROS accumulation leads to 
opening of MPTP, Cyt c release, irreversible damage of the 
respiratory chain, mitochondrial dysfunction and cell death. Figure is 





are unable to counterbalance the free radical production.  The free radicals oxidize 
the DNA, protein and lipids, which lead to mitochondrial dysfunction and cell death. 
 
1.1.2 Reperfusion injury 
During reperfusion, blood supply returns to the ischemic tissue. The reintroduction of 
oxygen activates XO that has accumulated during ischemia                             
(Granger and Kvietys, 2015). XO catalyzes conversion of hypoxanthine that has built 
up during ischemia to form xanthine. Xanthine is subsequently oxidized by XO to 
form uric acid. O2
•-
 and H2O2 are produced as byproducts of both oxidation 





Fenton reaction and Harber-Weiss reaction (Das et al., 2014). As a consequence, the 





OH which exacerbate the oxidative stress induced by ischemia. Besides, 
reperfusion also accelerates the neutrophil infiltration and pro-inflammatory 
mediators release (Schofield et al., 2013). Neutrophils consist of nicotinamide 
dinucleotide phosphate (NADPH) oxidase then reduces the oxygen to O2
•-
. Hence, 
neutrophil activation aggravates ROS formation in the reperfused tissue      
(Schofield et al., 2013). The inflammatory response also causes endothelial and 
parenchymal cell damage. Thus, reperfusion extends the ischemia-induced injuries, 
triggering more severe cascades of cell death. 
 
1.1.3 Current treatment for stroke 
The only US Food and Drug Administration (FDA)-approved thrombolytic drug to 
treat ischemic stroke is recombinant tissue plasminogen activator (r-tPA)            
(Roth, 2011). It is a clot busting drug that must be given to patients within 4.5 h after 
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stroke onset to restore the blood flow (Roth, 2011). Besides, r-tPA is only eligible for 
patients age 18-80 years old without prior history of both stroke and diabetes and not 
under oral anticoagulants prescription (Demaerschalk et al., 2015). Delayed r-tPA 
administration after 4.5 h could lead to dentrimental side effects such as intracerebral 
hemorrhagic transformation (HT) and blood brain barrier (BBB) rupture which 
contributes to high morbidity in patients (Wang et al., 2015). r-tPA cleaves the 
zymogen plasminogen to form activated plasmin which degrades the fibrin clot 
(Chevilley et al., 2015).  
 
Neuroendovascular procedures can be done within 6 h of first stroke symptoms and 
only after r-tPA administration provide better outcomes in patients                       
(Asil and Gultekin, 2016). During neuroendovascular procedures, a catheter is passed 
through the groin and navigated to the site of artery occlusion. The clot is then 
removed by the retrievable catheter. The narrow therapeutic window and strict 
eligibility criterias greatly impede effectiveness of treatment for majority 
ischemic stroke patients. Furthermore, none of these treatments have been 
successfully reversing the effect of ischemic stroke by regenerating new cells to 
replace the damaged brain tissue. As a consequence, stroke patients are usually 
associated with poor prognosis and high recurrent rate of stroke.  
 
 1.1.4 Stem cell therapy 
Since last few years, stem cell therapy has been the most encouraging approach for 
treating neurodegenerative diseases and stroke (Lunn et al., 2011; Kim et al., 2013; 
Kumar et al., 2016). The transplanted cells may help to create new circuitry and 
express factors that protect existing cells (De Feo et al., 2012). Neural stem cells 
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(NSCs) are considered as the most optimal cell type for stem cell-mediated therapy 
of brain disorders such as stroke (Kim et al., 2013). This is because they share the 
same tissue origin of the damaged brain cells and are originally meant to replenish 
the brain cells in vivo. In human brain, NSCs reside in two high-density cell division 
sites, the subventricular zone (SVZ) and subgranullar zone (SGZ) (Figure 1.6) 
(Gonzalez-Perez, 2012). NSCs are self renewal and able to differentiate into neuron, 
astrocyte and oligodendrocyte. They also have a lower oncogenic potential and 
immunological rejection (De Feo et al., 2012). Thus, NSCs provide the great 
potential for clinical applications.  
 
NSC transplantation has been studied in ischemic stroke animal models and human 
trial (Englund et al., 2002; Kelly et al., 2004; Date et al., 2006; Jin et al., 2011; 
Zhang et al., 2011; Muir and Sinden, 2015). Transplanted NSCs have been reported 
to contribute for neuroprotective effects in ischemic stroke. Several studies have 
demonstrated that transplanted NSCs could migrate to the ischemic areas, 
differentiate into mature neurons and even promote endogenous neurogenesis       
(Jin et al., 2011; Zhang et al., 2011; Mine et al., 2013). Besides, transplanted NSCs 
could ameliorate cerebral inflammation by reducing macrophage infiltration        
(Lee et al., 2008). Transplanted NSCs also promote angiogenesis at surrounding 
infarcted region through release of paracrine factors such as vascular endothelial 
growth factor A (VEGFA), angiopoietin-1 (ANGPT1), epidermal growth factor 
(EGF) and basic fibroblast growth factor (bFGF) (Hicks et al., 2013). Furthermore, 
Zhao and Wang (2013) demonstrated the anti-apoptotic effects of transplanted NSCs 
through enhanced mitogen-activated protein kinase/extracellular receptor kinase 





Figure 1.6 Coronal section of human adult brain. (A) NSCs reside within SVZ of 
the lateral ventricle (red boxes). (B) In adult hippocampus, NSCs are 














Despite the great therapeutic potential of NSCs for ischemic stroke, the survival of 
grafted cells within the infarcted area remains a serious concern for NSC 
transplantation. This is because the ischemic/reperfused region is very harsh for cell 
survival due to the excessive free radicals, glutamate excitotoxicity and inflammation. 
As little as 0.09% retention rate of grafted cells were observed in mice with transient 
middle cerebral artery occlusion (MCAO) (Bacigaluppi et al., 2009). Low cell 
survival rate limits the capacity of NSCs to repair the injured area and this poses a 
much more difficult challenge to the NSC-based therapy for ischemic stroke. To 
circumvent this problem, preconditioning of NSCs was employed. 
 
1.2 Preconditioning strategy 
The concept of preconditioning was first described in the past 30 years, whereby one 
or more brief episodes of sub-lethal stimuli was introduced to render the endogenous 
protective mechanisms against subsequent lethal injury (Murry et al., 1986). 
Preconditioning can be achieved through physiological sub-lethal stimuli such as 
hypoxia, heat shock and carbon monoxide (Sharp et al., 2004; Harder et al., 2005; 
Vieira et al., 2008). Besides, preconditioning can also be achieved through 
pharmacological agents such as minocycline, doxycycline, sevoflurane, cobalt 
chloride, baicalein and aromatic-tumerone (Wang et al., 2010a; Sakata et al., 2012; 
Wang et al., 2012; Chang et al., 2013; Dai et al., 2014; Hucklenbroich et al., 2014). 
This study focused on physiological and pharmacological preconditioning of NSCs 






1.2.1 Hypoxic preconditioning 
Hypoxic preconditioning involves brief periods of hypoxia that triggers various 
protective signaling pathways and enhances resilience to ischemia                     
(Sharp et al., 2004; Wei et al., 2017). Transcriptional responses to hypoxia are 
mediated by the hypoxia-inducible factor (HIF) (Sharp et al., 2004). Under hypoxia, 
activated HIF binds to hypoxia response elements (HREs) and subsequently activates 
expression of target genes involved in angiogenesis, energy metabolism and cell 
proliferation. Hypoxic preconditioning has been shown to promote NSC survival 
after transplantation into ischemic rat brain (Wakai et al., 2016). 
  
Besides, previous studies had reported that NSC microenvironment is hypoxic by 
nature, whereby the oxygen level in the brain may be as low as 2%                   
(Studer et al., 2000). Thus, in vitro cultivation of NSCs in a typical incubator 
condition of 21% oxygen does not reflect the physiologic norms. The normoxic 
condition is unlikely to be optimal for maintaining normal proliferative state of NSCs 
(Studer et al., 2000). Several studies have demonstrated that priming the endogenous 
NSCs using hypoxic preconditioning method can enhance the cell proliferation and 
differentiation in animal models (Giese et al., 2010; Wakai et al., 2016).  
 
1.2.2 Pharmacological preconditioning by baicalein-enriched fraction 
Pharmacological preconditioning involves brief periods of exposure to 
pharmacological agents that triggers intrinsic protective mechanisms and enhances 
resilience to subsequent lethal insults (Gidday, 2010). Baicalein                          
(5,6,7 trihydroxyflavone) is a flavonoid aglycan derived from Scutellaria baicalensis 
and Oroxylum indicum (Majeed et al., 2017). Like many flavonoid compounds, 
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baicalein can exert both antioxidant and pro-oxidant effects depending on cell types 
(Woo et al., 2005; Kang et al., 2012). Spectroscopic scanning measurements by   
Cho et al. (2008) revealed the binding of baicalein to prolyl hydroxylase 2 (PHD2) 
and factor inhibiting HIF-1 (FIH-1) under normoxia. Baicalein was found to compete 
with 2-oxoglutarate (2OG) for the active sites of PHD2 and FIH-1 through its          
3-hydroxyl structure. Hence, baicalein abrogated hydroxylation of hypoxia-inducible 
factor-1 alpha (HIF-1α) similar to those observed in hypoxic preconditioning. In 
addition, Chang et al. (2013) demonstrated that pharmacological pretreatment of 
chick cardiomyocytes using baicalein derived from S. baicalensis for 10 min prior to 
ischemia/reperfusion mediated a pro-oxidant preconditioning effects which mimicks 
hypoxic preconditioning. Consequently, pre-treatment with baicalein confered 
cytoprotection against ischemia and reperfusion injury in those cardiomyocytes and 
reduced apoptosis (Chang et al., 2013). The effects of baicalein on NSC have not 
been determined previously. Baicalein has been described to exert anti-proliferative 
and pro-proliferative activity depending on cell types. Baicalein treatment was found 
to attenuate proliferation of numerous human cancer cell lines (Cathcart et al., 2016; 
Bie et al., 2017; Zhou et al., 2017). However, it promoted proliferation in 
hematopoietic stem cells (Patwardhan et al., 2014). Hence, it is crucial to determine 
the effects of baicalein-enriched fraction particularly on NSCs. 
  
1.2.2(a)      Baicalein-enriched fraction from Oroxylum indicum  
Considering the promising neuroprotection potentials of baicalein, this study sought 
to produce an enriched baicalein fraction from the leaves of O. indicum as 
pharmacological agent for preconditioning. Besides O. indicum leaves, baicalein is 
also the major constituent in the roots of S. baicalensis (Aliev et al., 2014). However, 
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S. baicalensis requires destructive harvest which may lead to severe depletion of 
medicinal plant resources (Nishteswar, 2014). Hence, in this study, O. indicum 
leaves offer better resources without the removal of entire plant. 
 
Briefly, O. indicum is a medicinal herb belongs to family of Bignoniaceae that is 
commonly found in many regions of South-east Asia (Harminder et al., 2011). It is a 
deciduous soft wooded tree with pinnately compound, ovate-elliptic leaves and 
acuminate leaf tips (Figure 1.7A and B) (Harminder et al., 2011). This tree also has 
large flowers with stinky odour that bloom at night time to attract pollinators   
(Figure 1.7C). It also has long and flattened fruit pods that hang down from the thick 
branches like dangling swords (Figure 1.7D). When the pod burst, the flat and semi-
transparent winged seeds flutter like butterflies (Figure 1.7E). Hence, the seeds are 
known as “mu hu die” (tree butterfly) in Chinese herbal medicine                       
(Chen et al., 2003b). In Malaysia, it is commonly known as “Beko” and the young 
leaves as well as fruits are consumed raw as salad by the local community. Different 
parts of O. indicum such as fruits, root barks and leaves have been applied in 
traditional medicine to treat bronchitis, dyspepsia, asthma, gastropathy, inflammation 
and microbial infection (Harminder et al., 2011). Preconditioning by baicalein-
enriched fraction is also postulated to trigger similar neuroprotective mechanisms 




Figure 1.7 Representative images of O. indicum. (A) O. indicum is a medium-sized tree that branched at top. (B) The leaves are pinnately 
compound, ovate-elliptic with acuminate tips. (C) The flower emits strong and stinky smell to attract night pollinators. (D) Long 
and flattened fruit pods that hang down from the thick branches like dangling swords. (E) The seeds are flat with semi-transparent 






1.2.3 Preconditioning-induced neuroprotective signaling 
Physiological and pharmacological preconditioning have been reported to enhance 
resistance to lethal insults through activation of endogenous survival cascades such 
as HIF-1α, neurogenic locus notch homolog protein 1 (Notch 1), VEGFA, ANGPT1, 
nuclear factor erythroid 2-related factor 2 (Nrf2) and SOD1 (Figure 1.8)            
(Chen et al., 2003a; Belaidi et al., 2006; Stubbs et al., 2012; Zhou et al., 2013; 
Huang et al., 2014). 
 
1.2.3(a)      Hypoxia-inducible factor-1 alpha (HIF-1α) 
HIF-1 is a basic Helix-Loop-Helix-Period-Arnt-Single minded-homology       
(bHLH-PAS) domain transcription factor composed of an alpha (α) and a beta (β) 
subunit (Semenza et al., 1997). The oxygen-labile α subunits consisted of HIF-1α, 
HIF-2α and HIF-3α wherease β subunit, HIF-1β, is constitutively presented in the 
nucleus (Semenza et al., 1997). Apart from bHLH-PAS domain, HIF-1α also 
comprises of  transactivation domains (TAD) and oxygen-dependent degradation 
domain (ODD) as shown in Figure 1.9A (Semenza et al., 1997).  
 
HIF-1α expression is regulated by PHD2 and FIH-1. Under normoxic conditions, 
PHD2 catalyzes hydroxylation of two highly conserved proline residues (Pro402 and 
Pro564) within the ODD of HIF-1α (Figure 1.9B). The enzymatic process utilizes 
Fe
2+
 as co-factor whilst oxygen and 2OG as substrates. An E3 ubiquitin ligase 
complex known as von Hippel-Lindau (pVHL) further targets the hydroxylated    
HIF-1α for proteasomal degradation. In addition, FIH-1 catalyzes hydroxylation of 
asparagine residue (Asn803) within the C-TAD of HIF-1α (Figure 1.9C). Similar to 
PHD2, the hydroxylation requires Fe
2+




Figure 1.8 Preconditioning-induced neuroprotective signaling. Preconditioning 
modulated adaptive and recuperative mechanisms through HIF-1α, 
Notch 1, VEGFA, ANGPT1, Nrf2 and SOD1. HIF-1α enhanced 
VEGFA and ANGPT1 signaling to stimulate paracrine effects and 
angiogenesis whereas Nrf2-mediated SOD1 expression stimulates free 
radical scavenging. The crosstalk of HIF-1α and Nrf2 with Notch 1 



















Figure 1.9 Schema illustrating (A) HIF-1α domain structure, (B) PHD2 and      
(C) FIH-1 regulated HIF-1α degradation under normoxic conditions. 
(A) HIF-1α contain bHLH-PAS, TAD and ODDD. (B) Using oxygen, 
2OG and Fe
2+
, HIF-1α is degraded by PHD2 signaling. (C) FIH-1 also 
catalyzes hydroxylation of HIF-1α in the presence of oxygen, 2OG 
and Fe
2+
. Hydroxylated HIF-1α could not bind to CBP/p300 for 
downstream HIF-1α target genes. Hence, transcriptional activity of 
HIF-1α is inhibited (Masson and Ratcliffe, 2003). Figure is generated 
using Cell Illustrator 5 and Microsoft PowerPoint. 
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